The authors present an updated review of the clinical trials on hyperfractionated and accelerated fractionation schedules in radiotherapy of head and neck cancer. The available results in terms of survival and local control, and acute and late toxicity data are summarized in order to show the current status of this research field. The new breed of fractionation schedules that are on study, designed on the ground of new rationales, are presented as well. Finally, an introductory overview of combination therapy including non standard fractionation radiotherapy associated with chemotherapy is reported70.
AbitbolA.A., SchwadeJ.G., LewinA.A., SridharK., BrandonA.H., MarkalA.M., CasianoR.R., HoudekP.V., SeragoC., MillerD.J., HushM.S.: Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma: a pilot study. Am. J. Clin. Oncol., 15: 250–255, 1992.
2.
AngK., PetersL.: Concomitant boost radiotherapy in the treatment of head and neck cancers. Semin. Radiol. Oncol., 2: 31–33, 1992.
3.
AriasF., DominguezM.A., IllarramendiJ.J., MartinezE., TejedorM., DominguezS., DuenasM., VillafrancaE., El-carteF., MiquelizS., ValerdiJ.J.: Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report. Int. J. Radiat. Oncol. Biol. Phys., 33: 675–682, 1995.
4.
BeggA., HollandI., MoonenL., BartelinkH., SchraubS., BontempsP., Le FurR., Van den BogaertW., CaspersR., Van GlabbekeM., HoriotJ.: The predictive value of cell kinetics measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int. J. Radiat. Oncol. Biol. Phys., 19: 1449–1453, 1990.
5.
BeggA., HoflandI., Van GlabbekeM., BartelinkH., HoriotJ.C.: Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin. Radiol. Oncol., 2: 22–25, 1992.
6.
BentzenS.M.: Time-dose relationships for human tumors: estimation from nonrandomized studies. In: Current Topics in Clinical Radiobiology of Tumors, Beck-BornholdtH.P. (Ed.), pp. 11–26, Springer Verlag, Berlin, 1993.
7.
BourhisJ., FortinA., DupuisO., DomengeC., LusinchiA., MarandasP., SchwaabG., ArmandJ.P., LuboinskiB., MalaiseE., EschwegeP., WibaultP.: Very accelerated radiation therapy: preliminary results in locally unresectable head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys., 32: 747–752, 1995.
8.
BrizelD.M., LeopoldK.A., FisherS.R., PanellaT.J., FineR.L., BedrosianC.L., KenanP.D., HuangA., BjorstromT., DodgeR., ProsnitzL.R.: A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 28: 231–220, 1993.
9.
BrownmanG.P., CroninL.: Standard chemotherapy in squamous cell head and neck cancer: what have we learned from randomized trials. Semin. Oncol., 21: 311–319, 1994.
10.
ByhardtR.W.: Evolution of radiation therapy oncology Group (RTOG) protocols for nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 32: 1513–1525, 1995.
11.
ChoiK., RotmanM., AzizH., PottersL., StarkR., RosenthalJ.C.: Locally advanced paranasal sinus and nasopharynx tumors treated with hyperfractionated radiation and concomitant infusion cisplatin. Cancer, 67: 2748–2752, 1991.
12.
CorvòR., GiarettiW., SanguinetiG., GeidoE., OrecchiaR., BarraS., MargarinoG., BacigalupoA., VitaleV: Potential doubling time in head and neck tumors treated by primary radiotherapy: preliminary evidence for a prognostic significance in local control. Int. J. Radiat. Oncol. Biol. Phys., 27: 1165–1172, 1993.
13.
CorvòR., MerlanoM., SanguinetiG., BenassoM., GuenziM., CavallariM., BacigalupoA., MarzianoC., ChiarloneR., GrimaldiA., VitaleV: L'associazione chemio-radioterapica nei tumori inoperabili della testa e collo: revisione dell'esperienza genovese e studi in corso. In: Atti del 3° Congresso Nazionale AIRO, 605–609, Clas International Edizioni, Brescia-Italy, 1993.
14.
CoxJ., PajakT., MarcialV., CoiaL., MohiuddinM., FuK., SelimH., ByhardtR.W., RubinP., OrtizH., MartinL.: Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of respiratory/digestive tracts: new evidence for accelerated proliferation from RTOG protocol 83–13. Cancer, 69: 2744–2748, 1992.
15.
CoxJ., PajakT., MarcialV., CoiaL., MohiuddinM., FuK., SelimH., RubinP., OrtizH.: Astro plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313. Int. J. Radiat. Oncol. Biol. Phys., 20: 1191–1195, 1991.
16.
CoxJ., PajakT., MarcialV., HanksG., MohiuddinM., FuK., ByhardtR., RubinP.: Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of Radiation Therapy Oncology Group protocol 83–13. Int. J. Radiat. Oncol. Biol. Phys., 18: 515–521, 1990.
17.
DattaN.R., ChoudryA.D., GuptaS., BoseA.K.: Twice a day versus once a day radiation therapy in head and neck cancer (Abstr.). Int. J. Radiat. Oncol. Biol. Phys., 17 (Suppl 1): 132, 1989.
18.
DelaneyG.P., FisherR.J., SmeeR.I., HookC., BartonM.B.: Split-course accelerated therapy in head and neck cancer: an analysis of toxicity. Int. J. Radiat. Oncol. Biol. Phys., 32: 763–768, 1995.
Di StefanoA., JampolisS.L., BlumenscheinG.R., FirstembergB.A., KellyJ.P., Gomez-YeyilleJ.E.: Toxicity of combined cisplatin infusional 5-fluoruracil and concomitant radiotherapy in advanced head and neck cancer. In: Concomitant Continuous Infusion Chemotherapy and Radiation, RotmanM., RosenthalC.J. (Eds.), pp. 244–245, Springer Verlag, Berlin, 1991.
21.
DragovicJ.: Combined cisplatin and concomitant continuous infusion 5-fluorouracil and accelerated radiation in advanced head and neck cancer. In: Concomitant Continuous Infusion Chemotherapy and Radiation, RotmanM., RosenthalC.J. (Eds.), pp. 239–242, Springer Verlag, Berlin, 1991.
22.
FallaiC., OlmiP.: Altered fractionation schedules in radiotherapy of head and neck cancer. A review. Tumori, 78: 311–325, 1992.
23.
FallaiC., OlmiP., CellaiE.: Advanced carcinomas of the oropharynx treated with radiotherapy - A comparison of three different fractionation schemes. Am. J. Otolaryngol., 14: 31–37, 1993.
24.
FontanesiJ., BeckfordN.S., LesterE.P., KavanaughK.T., TaiD., EddyT., KunL.E.: Concomitant cisplatin and hyperfractionated external beam irradiation for advanced malignancy of the head and neck. Am. J. Surg., 162: 393–396, 1991.
FuK.K., CleryM., AngK.K., ByhardtR.W., MaorM.H., BeitlerJ.J.: Randomized phase I/II trial of two variants of accelerated radiotherapy regimens for advanced head and neck cancer; results of RTOG 88–09. Int. J. Radiat. Oncol. Biol. Phys., 32: 589–597, 1995.
27.
FuK.K., CoxJ.D.: Late effects of hyperfractionated radiation therapy for head and neck cancer. In response to Drs Withers and Taylor. Int. J. Radiat. Oncol. Biol. Phys., 32: 1266, 1995.
28.
FuK.K., PajakT.F., MarcialV.A., OrtizH.G., RotmanM., AsbellS.O., CoiaL.R., VoraN.L., ByhardtR., RubinP., SorgenS.D., CoxJ.D., StetzJ.: Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83–13. Int. J. Radiat. Oncol. Biol. Phys., 32: 577–588, 1995.
29.
GardenA.S., MorrisonW.H., AngK.K., PetersL.J.: Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules. Int. J. Radiat. Oncol. Biol. Phys., 31: 493–502, 1995.
30.
GiriS.P.G., TaylorS., GennerL., FabianC., DanielsH., BaughR.: Multiple fraction radiation therapy and cisplatin chemotherapy in advanced squamous cell cancers of the head and neck. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 11: A783, 1992.
31.
GlanzmannC., LusaefU.M.: Follow-up data of our pilot study on concomitant hyperfractionated radiotherapy and cisplatinum (CDDP) in patients with advanced cancer of the head and neck. Strahlenther. Onkol., 168: 453–456, 1992.
32.
HarariP.: Adding dose escalation to accelerated hyperfractionation for head and neck cancer: 76 Gy in 5 weeks. Semin. Radiol. Oncol., 2: 58–61, 1992.
33.
HarrisonL.B., PfisterD.G., ArmstrongJ.G., SessionsR.B., ShahJ.P., SpiroR.H., ElliotW.S., WeisenS., BoslG.J.: Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys.21: 703–708, 1991.
34.
HoriotJ.C., BeggA.C., Le FurR., SchraubS., Van Den BogaertW., Van GlabbekeM., PierartM.: Present status of EORTC trials of hyperfractionated and accelerated radiotherapy on head and neck carcinomas. Recent Results Cancer Res., 134: 111–119, 1994.
35.
HoriotJ.C., Le FurR., N'GuyenT., ChenalC., SchraubS., AlfonsiS., GardaniG., Van Den BogaertW., DanczakS., BollaM., Van GlabbekeM., De PauwM.: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol., 25: 231–241, 1992.
36.
HoriotJ.C., Le FurR., SchraubS., Van Den BogaertW., Van GlabbekeM., PierartM., BeggA.: Status of the EORTC Cooperative Group of radiotherapy with hyperfractionated and accelerated radiotherapy regimes. Semin. Radiol. Oncol., 2: 34–37, 1992.
37.
JohnsonC.R., Schmidt-UllrichR.K., ArthurD.W., HuangD.T., DuffyE.W.: Standard once-daily versus thrice daily concomitant boost accelerated superfractionated irradiation for advanced squamous cell carcinoma of the head and neck: preliminary results of a prospective randomized trial (Abst.). Int. J. Radiat. Oncol. Biol. Phys.32 (Suppl. 1): 162, 1995.
38.
JohnsonC.R., Schmidt-UllrichR., WazerD.: Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer, 69: 2749–2754, 1992.
39.
KarstensJ.H., SchnarkowskiP., LiL., MulkensP., SchlondorfF., AmmonJ.: Definitive radiochemotherapy in advanced head and neck cancer: a follow-up report of accelerated fractionated irradiation and a pilot study of mucositis prevention. Onkologie, 15: 156–159, 1992.
40.
LartigauE., SaundersM.I., DischeS., WarbustonM.F., Des RochersC.: A comparison of the late radiation changes after three schedules of radiotherapy. Radiother. Oncol., 20: 139–148, 1991.
41.
LeeD.J., CosmatosD., MarcialV.A., FuK.K., RotmanM., CooperJ.S., OrtizH.G., BeitlerJ., AbramsR.A., CurranW.J., ColemanC.N., WassermanT.H.:Results of an RTOG Phase III Trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys., 32: 567–576; 1995.
42.
LochrinC.A., WilsonG.D., McNallyN.J., DischeS., SaundersM.I.: Tumor cell kinetics, local tumor control, and accelerated radiotherapy: a preliminary report. Int. J. Radiat. Oncol. Biol. Phys., 24: 87–91, 1992.
43.
LusinchiA., LartigauE., LuboinskiB., EschwegeF.: Accelerated radiation therapy in the treatment of very advanced and inoperable head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys., 29: 149–152, 1994.
44.
MaciejewskiB., ZajuszA., PileckiB., SkladowskiK., DorrW., KummermherJ., TrottK.: Escalated hyperfractionation and stimulation of acute mucosal reaction in radiotherapy for cancer of the oral cavity and oropharynx. Semin. Radiol. Oncol.2: 54–57, 1992.
45.
MarcialV., PajakT., ChangC., TupchongL., StetzJ.: Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int. J. Radiat. Oncol. Biol. Phys., 13: 41–47, 1987.
46.
McGinnC.J., HarariP.M., FowlerJ.F., PyleG.M., KinsellaT.J.: Dose intensification in curative head and neck cancer radiotherapy - linear quadratic analysis and preliminary assessment of clinical results. Int. J. Radiat. Oncol. Biol. Phys., 27: 363–369, 1993.
47.
N'GuyenT.D., DeurangeL., FroissartD., PanisX., LoiretteM.: Clinical results in 178 advanced squamous cell carcinomas of the head and neck. Cancer, 56: 16–19, 1985.
48.
OlmiP., CellaiE., ChiavacciA., FallaiC.: Accelerated fractionation in advanced head and neck cancer: results and analysis of late sequelae. Radiother. Oncol., 17: 199–207, 1990.
49.
OlmiP., FallaiC., RossiF., CrispinoS., MarsoniS., TorriV., FlannM.: Conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus conventional radiotherapy and concomitant chemotherapy in advanced oropharyngeal carcinoma: a randomized clinical trial (Abst.). Eur. J. Cancer, 31A (Suppl 5): S 91, 1995.
50.
PetersL.J., AngK.K.: Altered fractionation schemes. In: Radiation Oncology: Technology and Biology, MauchP.M., LoefflerJ.S. (Eds.), pp. 545–565, W.B. Saunders, Philadelphia, 1994.
51.
PintoL., CanaryP., ArayoC., BacelarS., SouhamiL.: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 21: 557–562, 1991.
52.
SailerS.L., WeisslerM.C., MelinS.A., QaqishB.F., HoyleD., RosenmanJ.G., PillsburyH.C.: Toxicity and preliminary results from a trial of hyperfractionated radiation with or without simultaneous 5-FU/cisplatin in advanced head and neck squamous cell carcinoma. Semin. Radiol. Oncol., 2: 38–40, 1992.
53.
SanchizF., MillàA., TornerJ., BonetF., ArtolaN., CarrenoL., MoyaL., RieraD., RipolS., CireraL.: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 19: 1347–1350, 1990.
SaundersM., DischeS., GroschE., FermontD., AshfordR., MaherE., MakepeaceA.: Experience with CHART. Int. J. Radiat. Oncol. Biol. Phys., 21: 871–878, 1991.
56.
SchnabelT., ZamboglouN., KolotasC., HartmannA., SchmittG.: Combined radiochemotherapy with carboplatin in the treatment of advanced head and neck carcinomas. Oncology, 50(Suppl. 2): 16–22, 1993.
57.
SchnabelT., ZamboglouN., KolotasC., JimenezW., StrehlH., SchmittG.: Phase I study of hyperfractionated accelerated radiation therapy and simultaneous carboplatin for advanced head and neck carcinomas. Strahlenther. Onkol., 168: 318–321, 1992.
58.
SchwadeJ., MarkoeA., AbitbolA., LewinA., BrandonA., HoudekP., BraunscweigerP., CasianoR., SridharK., GoodwinW.: Accelerating hyperfractionation for carcinoma of the head and neck. Semin. Radiol. Oncol., 2: 51–53, 1992.
59.
ThamesH., PetersL., AngK.: Accelerated fractionation. In: Current topics in clinical radiobiology of tumors, Beck-BornholdtH.P. (Ed.), pp. 1–10, Springer Verlag, Berlin, 1993.
60.
Van den BogaertW., Van der SchuerenE., HoriotJ.C., ChaplainG., DevilhenaM., RaposoS., LeonorJ., SchraubS., ChenalC., BarthelmeE., DabanA., EschwegeF., GonzalezD., LeerJ., HamersH., SvobodaV., RigonA., ArcangeliG., SackH., De PauwM., Van GlabbekeM.: Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 12: 587–591, 1986.
61.
Van den BogaertW., Van der SchuerenE., HoriotJ.C., De VilhenaM., SchraubS., SvobodaV., ArcangeliG., De PauwM., Van GlabbekeM.: The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects. Radiother. Oncol., 35: 91–99, 1995.
62.
Van den BogaertW., Van der SchuerenE., HoriotJ.C., De VilhenaM., SchraubS., SvobodaV., ArcangeliG., De PauwM., Van GlabbekeM.: The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors. Radiother. Oncol., 35: 100–106, 1995.
63.
Van der SchuerenE., Van den BogaertW., VanuytselL., Van LimbergenE.: Radiotherapy by multiple fractions per day (MFD) in head and neck cancer: acute reactions of skin and mucosa. Int. J. Radiat. Oncol. Biol. Phys., 19: 301–311, 1990.
64.
WangC.C.: Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int. J. Radiat. Oncol. Biol. Phys., 14: 1143–1146, 1988.
65.
WangC.C.: Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx. Cancer, 63: 2461–2467, 1989.
66.
WangC.C.: Accelerated fractionation: the do's and don'ts - regarding Fu et al., Bourhis et al. and Delaney et al. IJROBP 32: 589–597, 1995. Int. J. Radiat. Oncol. Biol. Phys., 32: 889–890, 1995.
67.
WangC.C., EfirdJ., NakfoorB., MartinsP.: Local control of T3 carcinomas after accelerated fractionation - a look at the “gap”. Int. J. Radiat. Oncol. Biol. Phys., 35: 439–441, 1996.
68.
WeisslerM.C., MelinS., SailerS.L., QaqishB.F., RosenmanJ.G., PillsburyH.C.: Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Arch. Otolaryngol. Head Neck Surg., 118: 806–810, 1992.
69.
WendtT.G., HartensteinR.C., WustrowT.P.U., LissnerJ.: Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study. J. Clin. Oncol., 7: 471–476, 1989.
70.
WithersH.R.: Hyperfractionation. In: Current topics in clinical radiobiology of tumors, Beck-BornholdtH.P. (Ed.), pp. 45–50, Springer Verlag, Berlin, 1993.
